Loading...

Developing differentiated treatment options that address global unmet needs in multi-billion dollar markets

review our transforming drug-delivery platforms

Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.

Virpax’s transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to enhance compliance and to optimize the efficacy of our non-addictive pain management pipeline and our Central Nervous System (CNS) disorder pipeline.

Virpax’s non-addictive pain management pipeline is being developed to provide prescribers more treatment options to help individualized patient care. Once approved, these pain management alternatives may help patients achieve better health outcomes.

Virpax is traded on

(Nasdaq: VRPX)

View our presentation

OPTIMIZING NON-ADDICTIVE DRUG DELIVERY

IN THE TREATMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES

Probudur injection icon

Probudur™

Injectable liposomal hydrogel Bupivacaine

Probudur is the only liposomal hydro-gel bupivacaine formulation that has demonstrated 96 hours pain control administering a single injection at the wound site in head to head in-vivo studies.

More about Probudur
Envelta spray icon

Envelta™

Molecular Envelope Enkephalin Powder

Envelta is a patented intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.

More about Envelta
VRP324 spray icon

NobrXiol™

Molecular Envelope Cannabidiol Powder

NobrXiol is a patented pharmaceutical-grade cannabidiol intranasal spray powder being developed to manage Rare Pediatric Epilepsy (Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome).

More about NobrXiol

Rx Pipeline

Virpax’s proprietary Rx pipeline is well positioned to meet unmet needs in three multi-billion dollar markets.

View our pipeline

Global Sublicensing Strategy

We engaged Destum Partners to execute a global search for sublicensing partners.

VIEW OUR SUBLICENSING PIPELINE

Recent Press Releases

  • March 28, 2023

  • March 22, 2023

  • February 13, 2023

  • January 31, 2023

VIEW MORE

Recent Media

  • Feb 15, 2023

  • Feb 15, 2023

  • Jan 4, 2023

  • Jul 28, 2022

VIEW MORE

OUR MISSION

Our mission is to use our proprietary delivery platforms to optimize the efficacy of our non-addictive post operative pain, severe pain and CNS disorder product candidates.

We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide, including rare and orphan diseases.

“We’ve continued to support development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.”

ROBERT CALIFF

FDA Commissioner
ADVANCINGNON-ADDICTIVEPAIN MANAGEMENTWORLDWIDE

Experienced

executive leadership
Learn more

Robust

pipeline
Learn more
virpax pharma pain management mission

Explore our

Mission

new pain management solutions

Discover our

Products

Pain Management - Team

Meet our

Team

virpax pharmaceutical contact

Let’s

Connect